Realcan Pharmaceutical Group Co., Ltd. (REALCAN PHARMACEUTICAL GROUP CO) aksje

Realcan Pharmaceutical Group Co., Ltd. sells medicines, medical devices, and medical consumables to medical institutions in China. It operates through the Drug and Equipment Distribution, In Vitro Diagnostics, Pharmaceutical Logistics, Traditional Chinese Medicine, and Microbiome Medicine segments. The company engages in the processing, manufacture, sale, and wholesale of Chinese medicinal materials, herbal medicine, and patent medicine. It is also involved in the wholesale of biochemical, psychotropic, narcotic, and toxic drugs for medical use; chemical APIs, and preparations; antibiotics, biological products, anabolic steroids, peptide hormones, poppy shells, and pharmaceutical precursor chemicals; and medical devices. In addition, the company provides leasing of medical devices and technical services; investment management and consulting services; medical sterilization outsourcing and consulting services; health consulting services; and pharmaceutical logistics services. Further, it engages in the warehousing and distribution of drugs; technology development and transfer; and operation of a health service platform. The company was formerly known as Realcan Pharmaceutical Co., Ltd. and changed its name to Realcan Pharmaceutical Group Co., Ltd. in December 2018. Realcan Pharmaceutical Group Co., Ltd. was founded in 2004 and is based in Yantai, China.